The imaging technique at the heart of the study, positron emission tomography combined with computed tomography, has become a cornerstone of modern cancer care. Patients receive an injection of [18F]-fluorodeoxyglucose, a radioactive glucose analog that is avidly taken up by metabolically active cells. Because cancer cells typically consume glucose at a far higher rate than healthy tissue, they light up on the resulting images, allowing physicians to visualize both the primary tumor and any spread to lymph nodes or distant organs. The PET component reveals metabolic activity, while the CT component provides detailed anatomical context, and the fusion of the two gives clinicians a map of where active disease resides in the body.

In the standard workflow for locally advanced cervical cancer, PET-CT is used twice: once before treatment begins, to establish the stage of the disease, and again several weeks after chemoradiotherapy has concluded, to assess how well the cancer responded. The Swedish team set out to determine whether the information gathered at that second time point could do more than simply confirm whether the tumor had shrunk. They wanted to know whether the pattern of metabolic response could serve as a genuine prognostic instrument, capable of stratifying patients into distinct risk categories that would justify different follow-up strategies or, potentially, additional interventions.

To quantify treatment response, the researchers extracted three complementary parameters from every scan. The first and most widely used is SUVmax, the maximum standardized uptake value, which reflects the peak glucose metabolism within the most active region of a lesion. The second is metabolic tumour volume, or MTV, which measures the total physical volume of tissue exhibiting abnormally high FDG uptake. The third is total lesion glycolysis, or TLG, which combines volume and intensity into a single figure representing the overall metabolic burden carried by the disease. Each parameter captures a different dimension of tumor biology, and the team analyzed all three separately to see whether the more computationally demanding volume-based measures offered any advantage over the simple maximum uptake value.

Using these parameters, the investigators classified each patient’s post-treatment response into one of four categories adapted from established response criteria. A complete metabolic response, or CMR, meant the total resolution of abnormal FDG uptake in all lesions, essentially signaling that no metabolically active cancer could be detected anywhere in the scanned field. A partial metabolic response, or PMR, was defined as a reduction of more than 25 percent in SUVmax, MTV or TLG, indicating that disease remained but had been substantially weakened. Progressive metabolic disease, or PMD, was declared when uptake increased by more than 25 percent or when new FDG-avid lesions appeared, a clear sign that the treatment had failed to contain the cancer. Patients who fit none of these categories were classified as having stable disease. Because the number of events in the PMR and stable disease groups was limited, the researchers combined them into a single intermediate group for statistical analysis.

The results were striking. Taking patients with complete metabolic response as the reference group, those with partial response or stable disease faced roughly 1.2 times the odds of experiencing a recurrence, a modest but measurable elevation in risk. Far more dramatic was the picture for patients whose disease progressed: their odds of recurrence were 1.7 times higher when response was assessed by SUVmax, and 1.8 times higher when assessed by MTV or TLG. In other words, a scan showing growing or newly emerged metabolically active disease after treatment was a red flag that recurrence was substantially more likely, regardless of which of the three parameters was used to make the call.

The survival analysis carried an even starker message. Patients in the intermediate response group had a hazard ratio for death of 4.0 when response was measured by SUVmax, meaning their risk of dying during the follow-up period was four times that of patients who achieved a complete metabolic response. When MTV or TLG served as the response metric, the hazard ratio for this intermediate group was 2.9. For patients with progressive metabolic disease, the hazard ratio soared to 16.0 across all three parameters, a sixteen-fold increase in mortality risk compared with complete responders. The concordance index, a statistical measure of how well a model discriminates between patients with different outcomes, reached 0.84 for SUVmax-based models and 0.86 for models built on MTV or TLG, values that indicate strong predictive performance for any prognostic tool in oncology.

Perhaps the most consequential finding of the study is what it did not find: no meaningful superiority of the sophisticated volume-based parameters over the simple maximum uptake value. MTV and TLG require semi-automated segmentation of tumor volumes and considerably more computational processing, and some researchers have argued that their added information content should translate into better prognostic power. In this cohort, however, the three parameters performed in a nearly identical fashion, with concordance indices differing by only two hundredths. For clinical practice, this is genuinely good news, because it suggests that the prognostic value of post-treatment PET-CT can be unlocked using a parameter that is already routinely reported by nuclear medicine departments worldwide, without the need for new software, additional training or workflow changes.

The implications for patient management are considerable. Patients who achieve a complete metabolic response could potentially be spared intensive surveillance, receiving standard follow-up with the reassurance that their statistical outlook is excellent. Those with partial or stable metabolic response, whose risk is elevated but not extreme, might benefit from closer imaging intervals and a lower threshold for biopsy or salvage interventions. Patients showing progression on the post-treatment scan represent the group with the most urgent need for attention, and the sixteen-fold hazard ratio suggests that early escalation of care, whether through additional systemic therapy or enrollment in clinical trials of novel agents, could be life-extending for this small but high-risk population. The study also reinforces the value of performing a post-treatment PET-CT at all, since the metabolic information it provides clearly carries prognostic weight beyond anatomical assessment alone.

As with all retrospective single-center analyses, the findings come with caveats. The 133 patients were treated at a single Swedish institution, and the classification thresholds, including the 25 percent change criteria, were drawn from established response frameworks rather than derived de novo. Prospective validation in larger and more diverse cohorts will be needed before response category can be formally incorporated into treatment guidelines. Nevertheless, the strength and consistency of the associations, spanning recurrence risk, overall survival and three independent metabolic parameters, make a compelling case that the post-treatment FDG-PET/CT scan is far more than a formality. It is, in effect, a crystal ball of glucose metabolism, offering each patient and her medical team an early, individualized forecast of the road ahead, and pointing the way toward a future in which follow-up care for cervical cancer is tailored not to the average patient but to the biology revealed on a single scan.

Subject of Research: FDG-PET/CT-based treatment response assessment as a predictor of recurrence and survival in locally advanced cervical cancer

Article Title: FDG-PET/CT-based treatment response predicts recurrence and overall survival in locally advanced cervical cancer

Article References: Markus, M., Sartor, H., Bjurberg, M., Minarik, D., & Trägårdh, E. (2026). FDG-PET/CT-based treatment response predicts recurrence and overall survival in locally advanced cervical cancer. BMC Medical Imaging, 26(1), Article 458. https://doi.org/10.1186/s12880-026-02772-8

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02772-8

Keywords: FDG-PET/CT, cervical cancer, treatment response, SUVmax, metabolic tumour volume, total lesion glycolysis, recurrence, overall survival, radiotherapy, nuclear medicine, predictive medicine, oncology

The biological centerpiece of this framework is metabolic reprogramming, one of the updated Hallmarks of Cancer. Head and neck squamous cell carcinoma cells rely heavily on aerobic glycolysis, the so-called Warburg effect, burning through enormous quantities of glucose and converting it to lactate even in the presence of oxygen. This inefficient ATP generation might seem like a design flaw, but it allows rapid proliferation and creates a continuous drain on the body’s nutrient supply. The lactate released by tumors does not simply disappear; it enters the Cori cycle, forcing the liver to spend energy converting it back into glucose through gluconeogenesis. The result is a futile substrate loop that raises resting energy expenditure and contributes to the hypermetabolic state long observed in cancer patients.

The review emphasizes that the tumor behaves, in the authors’ framing, as a metabolic sink. Glucose, lipids, and amino acids are redirected from skeletal muscle, liver, and adipose tissue toward the growing malignancy. Cytokine-driven activation of proteolytic pathways in muscle triggers the breakdown of contractile proteins and the release of glutamine and other amino acids that can be funneled into tumor metabolism. Meanwhile, tumor-derived factors such as parathyroid hormone-related protein promote lipolysis and the browning of white adipose tissue, converting energy stored in fat into heat rather than usable fuel. These processes, the authors stress, do not directly nourish the tumor; instead, they force the host to mobilize substrates in a losing attempt to maintain homeostasis, producing thermogenic inefficiency and accelerating energy wasting.

Chronic systemic inflammation amplifies this catabolic storm. Elevated circulating levels of interleukin-6, tumor necrosis factor-alpha, and interleukin-1 beta are commonly found in head and neck cancer patients and correlate with weight loss, sarcopenia, and poorer clinical outcomes. Interleukin-6 has been strongly linked to loss of body mass and adipose tissue depletion, while tumor necrosis factor-alpha enhances ubiquitin-proteasome-mediated protein degradation and impairs glucose transport in peripheral tissues. Within skeletal muscle, activation of the myostatin/SMAD signaling pathway suppresses protein synthesis and accelerates atrophy. Together, these mechanisms create a self-perpetuating loop in which inflammation sustains catabolism, tissue wasting further fuels inflammatory signaling, and the patient’s metabolic reserve erodes progressively, often before any anticancer therapy has begun.

This model explains a clinical observation that has long puzzled oncologists: many patients lose weight and muscle mass early in the disease course, even when their oral intake appears adequate, and caloric supplementation alone frequently fails to prevent muscle loss or cachexia. The internationally accepted GLIM criteria for diagnosing malnutrition already recognize inflammation as a key etiologic driver, requiring at least one phenotypic criterion such as weight loss or reduced muscle mass alongside an etiologic criterion such as reduced intake or disease-related inflammation. The new review goes further, arguing that in head and neck cancer the inflammatory and metabolic components dominate, and that nutritional impairment should be viewed as a dynamic, tumor-driven process rather than a simple caloric deficit.

Translating this biology into measurable clinical tools is where the review makes its most distinctive contribution. Sarcopenia, the progressive loss of skeletal muscle, is one of the most clinically relevant manifestations of cancer-related metabolic derangement. Because patients with head and neck cancer rarely undergo routine abdominal imaging, cross-sectional muscle assessment at the level of the third cervical vertebra has emerged as a validated surrogate for whole-body muscle mass. The resulting C3 skeletal muscle index can identify muscle depletion that body mass index misses entirely, and it carries prognostic weight: sarcopenia has been consistently associated with poorer overall survival, increased treatment-related toxicity, and reduced quality of life, making it a robust biomarker rather than a mere byproduct of treatment intolerance.

On the metabolic side, functional imaging offers a window into the tumor’s glycolytic appetite. Total lesion glycolysis, derived from 18F-FDG PET scans, integrates tumor volume with metabolic activity to reflect the overall glucose consumption of the malignancy. High values have been associated with aggressive tumor biology, greater inflammatory burden, and adverse oncologic outcomes. Crucially, recent prospective data in locally advanced head and neck squamous cell carcinoma showed that higher tumor metabolic activity measured by total lesion glycolysis was significantly associated with reduced skeletal muscle mass at the third cervical vertebra, elevated inflammatory markers, and impaired nutritional status at the start of treatment. This provides clinical validation of the biological model: tumor-driven hypermetabolism and inflammation translate into measurable deterioration of body composition and nutritional reserve.

The authors are careful to acknowledge the limitations of the current evidence base. The studies linking PET-derived metabolic parameters with nutritional impairment remain limited in number and observational in design, and external validation in larger prospective cohorts is still needed. Methodological heterogeneity in PET acquisition protocols, lesion segmentation strategies, and cutoff values complicates comparisons across studies, and standardized imaging protocols and universally accepted thresholds for C3-based muscle assessment have not yet been fully established. Metabolic imaging biomarkers should therefore be considered complementary tools alongside conventional nutritional and body composition assessment rather than stand-alone diagnostic markers. In practice, the review advocates a multimodal approach combining clinical nutritional evaluation, C3-derived muscle assessment when available, inexpensive and widely accessible inflammatory markers such as C-reactive protein and the neutrophil-to-lymphocyte ratio, and metabolic imaging parameters in patients already undergoing PET imaging.

The therapeutic implications are perhaps the most consequential part of the framework. If malnutrition is an immune-metabolic syndrome, then early nutritional intervention should aim not merely to increase calories but to modulate systemic inflammation and preserve functional body composition. Current European Society for Clinical Nutrition and Metabolism guidelines support early nutritional intervention as a cornerstone of multidisciplinary care in head and neck oncology, and intervention appears most effective during the pre-cachectic or early cachectic phases, when metabolic alterations remain potentially reversible. Immunonutrition enriched with arginine, omega-3 fatty acids, and nucleotides has shown promising effects, including improvement of the CD4/CD8 T-cell balance and accelerated postoperative recovery, but the evidence remains heterogeneous, and the authors caution that adequately powered randomized trials are needed before routine use beyond current guideline indications can be recommended.

Patients with locally advanced disease, high tumor metabolic burden, marked systemic inflammation, and early muscle depletion are especially vulnerable, as are those with advanced age, HPV-negative tumors, extensive smoking histories, dysphagia, or treatment with concurrent chemoradiotherapy. For these individuals, the review argues, nutritional management should prioritize preservation of lean body mass over weight maintenance alone, with adequate protein and energy provision embedded in integrated supportive care that includes pain control and oncologic treatment planning. Nutritional support alone is unlikely to fully reverse the underlying immune-metabolic alterations, but early recognition of high-risk features could shift the paradigm from reactive nutritional rescue to proactive metabolic management. By uniting tumor metabolism, systemic inflammation, and imaging-based body composition into a single conceptual framework, the Naples team offers oncologists a way to identify vulnerable patients before cachexia takes hold, and a biological rationale for treating the tumor’s metabolic sabotage, not just the patient’s empty plate, as the true target of nutritional care in head and neck cancer.

Subject of Research: Tumor-driven immune-metabolic mechanisms of cancer-related malnutrition in head and neck squamous cell carcinoma

Article Title: Beyond reduced intake: tumor metabolism and immune dysregulation drive cancer-related malnutrition in head and neck squamous cell carcinoma (HNSCC)

Article References: Zurlo, V., Piccirillo, A., Marciano, M. L., Pontone, M., Rampetta, F. R., Perri, E., & Perri, F. (2026). Beyond reduced intake: tumor metabolism and immune dysregulation drive cancer-related malnutrition in head and neck squamous cell carcinoma (HNSCC). Supportive Care in Cancer, 34(10), Article 1056. https://doi.org/10.1007/s00520-026-11115-w

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11115-w

Keywords: head and neck cancer, cancer-related malnutrition, sarcopenia, tumor metabolism, Warburg effect, systemic inflammation, immunonutrition, total lesion glycolysis, C3 skeletal muscle index, cachexia, PET imaging, nutritional intervention